解构明知

R. Booth
{"title":"解构明知","authors":"R. Booth","doi":"10.2139/ssrn.3826619","DOIUrl":null,"url":null,"abstract":"In a typical securities fraud class action (SFCA) against a publicly traded company under SEC Rule 10b-5, the claim arises from an alleged cover-up of bad news by company agents. When the truth comes out, stock price drops, and fraud-period buyers sue to recover their losses. In most such cases, the merits of the claim turn on whether the plaintiff can plead (and ultimately prove) scienter – a wrongful state of mind – on the part of those who spoke falsely for the corporation. Moreover, the scienter of the speaker must be imputed to the corporation if the corporation is to be held liable. But the definition of scienter is nebulous at best – and especially so because securities fraud of the sort just described typically does not involve any gain for the corporation-defendant. If nothing is to be gained by the corporation-defendant, the alleged deception may be merely accidental or careless. So how do we separate the meritorious wheat from the dismissible chaff? What does it take to plead scienter in a situation in which the speaker is not obviously motivated by the prospect of gain?<br><br>The definition of scienter has evolved significantly since 1976 when it was first held by SCOTUS to be a required element of any claim under Rule 10b-5. At first, the Court defined scienter simply as a mental state embracing intent to deceive, manipulate, or defraud. The Court also acknowledged at the time that recklessness might suffice to show scienter. But so to define scienter is merely to kick the can down the road. What exactly does it mean to say that recklessness will suffice to prove scienter? The Court has repeatedly declined to require that any motive be pleaded, while itself freely discussing motive when it seems relevant. Thus, lower courts (and plaintiffs) are left to explain why a defendant corporation (or its agents acting on its behalf) would want to mislead the market when the truth is bound to come out anyway. The idea that a corporate agent might lie to the market for no reason at all would seem to suggest that negligence will suffice – which is contrary to the rationale for the scienter requirement – or that the defendant bears the burden of proof that the statement in question was made without scienter – which is contrary to the heightened pleading standard applicable to scienter.<br><br>Cleverly, SCOTUS has alluded to a possible alternative standard in a series of securities cases not involving Rule 10b-5. The genuine belief test asks whether the corporate spokesperson could or should reasonably believe their own words given known or knowable facts. This is essentially the same standard as the reasonable basis test, which has been applied in the context of actions against broker-dealers and investment advisers since the 1940s. In contrast to the traditional approach to scienter, the genuine-belief reasonable-basis (GBRB) test is an objective one that does not require any reference to motive. It does not rely on any explanation of why a corporate agent might want to deceive the market. <br><br>The question remains whether the scienter of a corporate agent in connection with a voluntary statement can be imputed to the corporation. As the few courts that have considered it have ruled, the answer to this question is a matter of agency law. But most courts have stopped short of providing a complete answer by relying on the doctrines of vicarious liability or apparent authority. Both answers are problematic. The former imposes strict or absolute liability and is thus inconsistent with the scienter requirement. The latter leaves open the possibility that the corporate agent who speaks to the market may have gone rogue in which case the principal corporation would have a claim against its own agent for any harm it suffers. But the imputation issue does not arise in cases in which the speaker acts with actual authority – rather than merely apparent authority – or where the corporation ratifies deception by failing promptly to correct.<br><br>This article traces the evolution of scienter as applied under Rule 10b-5 primarily by analysis of SCOTUS decisions addressing the concept. It contributes to the law and literature by demonstrating the relevance of agency law doctrine, which has been almost entirely ignored by other scholarship on the subject of scienter. <br>","PeriodicalId":289542,"journal":{"name":"CGN: Securities Litigation (Sub-Topic)","volume":"136 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Deconstructing Scienter\",\"authors\":\"R. Booth\",\"doi\":\"10.2139/ssrn.3826619\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In a typical securities fraud class action (SFCA) against a publicly traded company under SEC Rule 10b-5, the claim arises from an alleged cover-up of bad news by company agents. When the truth comes out, stock price drops, and fraud-period buyers sue to recover their losses. In most such cases, the merits of the claim turn on whether the plaintiff can plead (and ultimately prove) scienter – a wrongful state of mind – on the part of those who spoke falsely for the corporation. Moreover, the scienter of the speaker must be imputed to the corporation if the corporation is to be held liable. But the definition of scienter is nebulous at best – and especially so because securities fraud of the sort just described typically does not involve any gain for the corporation-defendant. If nothing is to be gained by the corporation-defendant, the alleged deception may be merely accidental or careless. So how do we separate the meritorious wheat from the dismissible chaff? What does it take to plead scienter in a situation in which the speaker is not obviously motivated by the prospect of gain?<br><br>The definition of scienter has evolved significantly since 1976 when it was first held by SCOTUS to be a required element of any claim under Rule 10b-5. At first, the Court defined scienter simply as a mental state embracing intent to deceive, manipulate, or defraud. The Court also acknowledged at the time that recklessness might suffice to show scienter. But so to define scienter is merely to kick the can down the road. What exactly does it mean to say that recklessness will suffice to prove scienter? The Court has repeatedly declined to require that any motive be pleaded, while itself freely discussing motive when it seems relevant. Thus, lower courts (and plaintiffs) are left to explain why a defendant corporation (or its agents acting on its behalf) would want to mislead the market when the truth is bound to come out anyway. The idea that a corporate agent might lie to the market for no reason at all would seem to suggest that negligence will suffice – which is contrary to the rationale for the scienter requirement – or that the defendant bears the burden of proof that the statement in question was made without scienter – which is contrary to the heightened pleading standard applicable to scienter.<br><br>Cleverly, SCOTUS has alluded to a possible alternative standard in a series of securities cases not involving Rule 10b-5. The genuine belief test asks whether the corporate spokesperson could or should reasonably believe their own words given known or knowable facts. This is essentially the same standard as the reasonable basis test, which has been applied in the context of actions against broker-dealers and investment advisers since the 1940s. In contrast to the traditional approach to scienter, the genuine-belief reasonable-basis (GBRB) test is an objective one that does not require any reference to motive. It does not rely on any explanation of why a corporate agent might want to deceive the market. <br><br>The question remains whether the scienter of a corporate agent in connection with a voluntary statement can be imputed to the corporation. As the few courts that have considered it have ruled, the answer to this question is a matter of agency law. But most courts have stopped short of providing a complete answer by relying on the doctrines of vicarious liability or apparent authority. Both answers are problematic. The former imposes strict or absolute liability and is thus inconsistent with the scienter requirement. The latter leaves open the possibility that the corporate agent who speaks to the market may have gone rogue in which case the principal corporation would have a claim against its own agent for any harm it suffers. But the imputation issue does not arise in cases in which the speaker acts with actual authority – rather than merely apparent authority – or where the corporation ratifies deception by failing promptly to correct.<br><br>This article traces the evolution of scienter as applied under Rule 10b-5 primarily by analysis of SCOTUS decisions addressing the concept. It contributes to the law and literature by demonstrating the relevance of agency law doctrine, which has been almost entirely ignored by other scholarship on the subject of scienter. <br>\",\"PeriodicalId\":289542,\"journal\":{\"name\":\"CGN: Securities Litigation (Sub-Topic)\",\"volume\":\"136 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-04-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CGN: Securities Litigation (Sub-Topic)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2139/ssrn.3826619\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CGN: Securities Litigation (Sub-Topic)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/ssrn.3826619","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

根据美国证券交易委员会10b-5规则,针对上市公司的典型证券欺诈集体诉讼(SFCA)中,索赔源于公司代理人涉嫌掩盖坏消息。当真相大白时,股价就会下跌,欺诈期的买家就会起诉以追回损失。在大多数此类案件中,索赔的价值取决于原告是否能够为那些为公司作虚假陈述的人辩护(并最终证明)科学——一种错误的精神状态。此外,如果公司要承担责任,则演讲者的中心必须归咎于公司。但是,科学的定义充其量是模糊的,尤其是因为刚刚描述的那种证券欺诈通常不涉及被告公司的任何利益。如果公司被告得不到任何好处,那么所谓的欺骗可能仅仅是偶然的或粗心的。那么,我们如何将有价值的小麦与无用的谷壳区分开来呢?在讲话者显然不是为了获得利益而说话的情况下,怎样才能恳求科学呢?自1976年以来,科学的定义发生了重大变化,当时最高法院首次将其视为规则10b-5下任何索赔的必要要素。起初,法院简单地将欺骗定义为一种包含欺骗、操纵或欺诈意图的精神状态。法院当时也承认,鲁莽可能足以证明科学。但是,给科学下定义只不过是把问题推到后面去。说鲁莽足以证明科学,这到底是什么意思?本院一再拒绝要求提出任何动机的辩护,而自己却在似乎有关的情况下自由讨论动机。因此,低级法院(和原告)只能解释为什么被告公司(或其代理人代表其行事)想要误导市场,而真相无论如何都会浮出水面。公司代理人可能毫无理由地向市场撒谎的想法似乎表明,过失就足够了——这与科学要求的基本原理相反——或者被告承担举证责任,证明有关陈述是在没有科学的情况下作出的——这与适用于科学的高级辩护标准相反。聪明的是,SCOTUS在一系列不涉及规则10b-5的证券案件中暗示了一个可能的替代标准。真实信念测试的问题是,在已知或可知的事实下,公司发言人是否能够或应该合理地相信自己的话。这一标准与合理基础测试基本相同,后者自上世纪40年代以来一直适用于针对经纪自营商和投资顾问的诉讼。与传统的科学检验方法相比,真实信念合理基础检验(GBRB)是一种不需要任何动机参考的客观检验方法。它不依赖于对企业代理为何想要欺骗市场的任何解释。问题仍然是,公司代理人与自愿陈述有关的责任能否归责于公司。正如少数几个考虑过这个问题的法院所裁决的那样,这个问题的答案是代理法的问题。但是,大多数法院依靠替代责任或表面权威的理论,没有提供一个完整的答案。这两个答案都有问题。前者规定了严格责任或绝对责任,因此与科学要求不一致。后者留下了这样一种可能性,即与市场对话的公司代理人可能已经失控,在这种情况下,主要公司将有权就其遭受的任何损害向自己的代理人提出索赔。但是,在发言者行使实际权力(而不仅仅是表面上的权力)或公司因未能及时纠正而批准欺骗行为的情况下,就不会出现归责问题。本文主要通过分析美国联邦最高法院关于这一概念的判决,追溯了适用于规则10b-5的“科学中心”的演变。它通过展示代理法理论的相关性对法律和文学做出了贡献,而这一相关性几乎完全被其他关于科学的学术所忽视。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Deconstructing Scienter
In a typical securities fraud class action (SFCA) against a publicly traded company under SEC Rule 10b-5, the claim arises from an alleged cover-up of bad news by company agents. When the truth comes out, stock price drops, and fraud-period buyers sue to recover their losses. In most such cases, the merits of the claim turn on whether the plaintiff can plead (and ultimately prove) scienter – a wrongful state of mind – on the part of those who spoke falsely for the corporation. Moreover, the scienter of the speaker must be imputed to the corporation if the corporation is to be held liable. But the definition of scienter is nebulous at best – and especially so because securities fraud of the sort just described typically does not involve any gain for the corporation-defendant. If nothing is to be gained by the corporation-defendant, the alleged deception may be merely accidental or careless. So how do we separate the meritorious wheat from the dismissible chaff? What does it take to plead scienter in a situation in which the speaker is not obviously motivated by the prospect of gain?

The definition of scienter has evolved significantly since 1976 when it was first held by SCOTUS to be a required element of any claim under Rule 10b-5. At first, the Court defined scienter simply as a mental state embracing intent to deceive, manipulate, or defraud. The Court also acknowledged at the time that recklessness might suffice to show scienter. But so to define scienter is merely to kick the can down the road. What exactly does it mean to say that recklessness will suffice to prove scienter? The Court has repeatedly declined to require that any motive be pleaded, while itself freely discussing motive when it seems relevant. Thus, lower courts (and plaintiffs) are left to explain why a defendant corporation (or its agents acting on its behalf) would want to mislead the market when the truth is bound to come out anyway. The idea that a corporate agent might lie to the market for no reason at all would seem to suggest that negligence will suffice – which is contrary to the rationale for the scienter requirement – or that the defendant bears the burden of proof that the statement in question was made without scienter – which is contrary to the heightened pleading standard applicable to scienter.

Cleverly, SCOTUS has alluded to a possible alternative standard in a series of securities cases not involving Rule 10b-5. The genuine belief test asks whether the corporate spokesperson could or should reasonably believe their own words given known or knowable facts. This is essentially the same standard as the reasonable basis test, which has been applied in the context of actions against broker-dealers and investment advisers since the 1940s. In contrast to the traditional approach to scienter, the genuine-belief reasonable-basis (GBRB) test is an objective one that does not require any reference to motive. It does not rely on any explanation of why a corporate agent might want to deceive the market.

The question remains whether the scienter of a corporate agent in connection with a voluntary statement can be imputed to the corporation. As the few courts that have considered it have ruled, the answer to this question is a matter of agency law. But most courts have stopped short of providing a complete answer by relying on the doctrines of vicarious liability or apparent authority. Both answers are problematic. The former imposes strict or absolute liability and is thus inconsistent with the scienter requirement. The latter leaves open the possibility that the corporate agent who speaks to the market may have gone rogue in which case the principal corporation would have a claim against its own agent for any harm it suffers. But the imputation issue does not arise in cases in which the speaker acts with actual authority – rather than merely apparent authority – or where the corporation ratifies deception by failing promptly to correct.

This article traces the evolution of scienter as applied under Rule 10b-5 primarily by analysis of SCOTUS decisions addressing the concept. It contributes to the law and literature by demonstrating the relevance of agency law doctrine, which has been almost entirely ignored by other scholarship on the subject of scienter.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信